141 related articles for article (PubMed ID: 18793581)
1. Tafluprost, a new potent prostanoid receptor agonist: a dose-response study on pharmacodynamics and tolerability in healthy volunteers.
Sutton A; Gouws P; Ropo A
Int J Clin Pharmacol Ther; 2008 Aug; 46(8):400-6. PubMed ID: 18793581
[TBL] [Abstract][Full Text] [Related]
2. A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males.
Sutton A; Gilvarry A; Ropo A
J Ocul Pharmacol Ther; 2007 Aug; 23(4):359-65. PubMed ID: 17803434
[TBL] [Abstract][Full Text] [Related]
3. The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice.
Ota T; Aihara M; Saeki T; Narumiya S; Araie M
Br J Ophthalmol; 2007 May; 91(5):673-6. PubMed ID: 17124244
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma.
Holló G; Katsanos A
Expert Opin Drug Saf; 2015 Apr; 14(4):609-17. PubMed ID: 25640746
[TBL] [Abstract][Full Text] [Related]
5. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
[TBL] [Abstract][Full Text] [Related]
6. A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components.
Pfeiffer N; Traverso CE; Lorenz K; Saarela V; Liinamaa J; Uusitalo H; Astakhov Y; Boiko E; Ropo A;
Adv Ther; 2014 Dec; 31(12):1228-46. PubMed ID: 25447269
[TBL] [Abstract][Full Text] [Related]
7. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost.
Traverso CE; Ropo A; Papadia M; Uusitalo H
J Ocul Pharmacol Ther; 2010 Feb; 26(1):97-104. PubMed ID: 20148656
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug.
Takagi Y; Nakajima T; Shimazaki A; Kageyama M; Matsugi T; Matsumura Y; Gabelt BT; Kaufman PL; Hara H
Exp Eye Res; 2004 Apr; 78(4):767-76. PubMed ID: 15037111
[TBL] [Abstract][Full Text] [Related]
9. Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation.
Ota T; Murata H; Sugimoto E; Aihara M; Araie M
Invest Ophthalmol Vis Sci; 2005 Jun; 46(6):2006-11. PubMed ID: 15914616
[TBL] [Abstract][Full Text] [Related]
10. The circadian changes of intraocular pressure and ocular perfusion pressure after tafluprost compared with travoprost in normal tension glaucoma.
Shin J; Lee JW; Choi BS; Yun EY; Jung JH; Kim EA; Caprioli J
J Ocul Pharmacol Ther; 2014 Dec; 30(10):803-9. PubMed ID: 25285367
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis.
Hamacher T; Airaksinen J; Saarela V; Liinamaa MJ; Richter U; Ropo A
Acta Ophthalmol Suppl (Oxf ); 2008; 242():14-9. PubMed ID: 18752510
[TBL] [Abstract][Full Text] [Related]
12. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
[TBL] [Abstract][Full Text] [Related]
13. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW
Am J Ophthalmol; 2012 Jun; 153(6):1187-96. PubMed ID: 22310086
[TBL] [Abstract][Full Text] [Related]
14. Tafluprost: a novel prostaglandin analog for treatment of glaucoma.
Pantcheva MB; Seibold LK; Awadallah NS; Kahook MY
Adv Ther; 2011 Sep; 28(9):707-15. PubMed ID: 21858491
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredients.
Holló G; Hommer A; Antón López A; Ropo A
J Ocul Pharmacol Ther; 2014 Aug; 30(6):468-75. PubMed ID: 24738883
[TBL] [Abstract][Full Text] [Related]
16. Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Effectiveness and Treatment Persistence.
Kuwayama Y; Hashimoto M; Kakegawa R; Nomura A; Shimada F
Adv Ther; 2017 Jun; 34(6):1411-1425. PubMed ID: 28502035
[TBL] [Abstract][Full Text] [Related]
17. Benefits of Tafluprost and Timolol Fixed-Dose Combination for the Treatment of Glaucoma Are Confirmed by Studies on Experimental Animal Models.
Akaishi T; Shimazaki A; Tonouchi A; Ueda K; Miyawaki N; Kawazu K
J Ocul Pharmacol Ther; 2015 Nov; 31(9):518-24. PubMed ID: 26325164
[TBL] [Abstract][Full Text] [Related]
18. Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination.
Fuwa M; Ueda K; Akaishi T; Yamashita N; Kirihara T; Shimazaki A; Mano H; Kawazu K
PLoS One; 2016; 11(7):e0158797. PubMed ID: 27383260
[TBL] [Abstract][Full Text] [Related]
19. Metabolism and ocular tissue distribution of an antiglaucoma prostanoid, tafluprost, after ocular instillation to monkeys.
Fukano Y; Kawazu K; Akaishi T; Bezwada P; Pellinen P
J Ocul Pharmacol Ther; 2011 Jun; 27(3):251-9. PubMed ID: 21491995
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.
Uusitalo H; Pillunat LE; Ropo A;
Acta Ophthalmol; 2010 Feb; 88(1):12-9. PubMed ID: 20420586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]